^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    albumin-bound paclitaxel

    i
    Other names: ABI007, ABI-007, SNA-001, HC007
    Company:
    Generic mfg.
    Drug class:
    Tubulin inhibitor
    Related drugs:
    1m
    FREEDOM: Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer (clinicaltrials.gov)
    P=N/A, N=150, Recruiting, Harbin Medical University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    paclitaxel • docetaxel • albumin-bound paclitaxel • irinotecan • Fruzaqla (fruquintinib)
    1m
    Impact of Thyroid Transcription Factor-1 Expression on Outcomes of Platinum-Based Chemoimmunotherapy in Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer. (PubMed, Thorac Cancer)
    Platinum/PEM/Pembro may be a therapeutic option for TTF-1-negative non-sq NSCLC with good PS and adenocarcinoma histology, although careful management of irAE is required.
    Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    TTF1 (Transcription Termination Factor 1) • NKX2-1 (NK2 Homeobox 1)
    |
    Keytruda (pembrolizumab) • Tecentriq (atezolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed
    1m
    Neoadjuvant Short-Course Radiotherapy Plus Tislelizumab and Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Tang-Du Hospital
    New P2 trial
    |
    carboplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel
    1m
    A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation (clinicaltrials.gov)
    P1/2, N=222, Not yet recruiting, Genfleet Therapeutics (Shanghai) Inc.
    New P1/2 trial
    |
    KRAS (KRAS proto-oncogene GTPase) • RAS (Rat Sarcoma Virus)
    |
    KRAS mutation • RAS mutation
    |
    Erbitux (cetuximab) • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium
    1m
    Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC (clinicaltrials.gov)
    P2, N=160, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • Sulanda (surufatinib)
    1m
    EA1181: CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy (clinicaltrials.gov)
    P2, N=2175, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Trial primary completion date: Oct 2026 --> Oct 2027
    Trial primary completion date
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 negative
    |
    Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • albumin-bound paclitaxel • Trazimera (trastuzumab-qyyp)
    1m
    A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor (clinicaltrials.gov)
    P1/2, N=120, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • capecitabine • albumin-bound paclitaxel • trastuzumab rezetecan (SHR-A1811)
    1m
    DESTINY Breast Respond HER2-(Ultra)Low Europe (clinicaltrials.gov)
    P=N/A, N=2295, Recruiting, Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | N=1155 --> 2295 | Trial completion date: Sep 2028 --> Dec 2030 | Trial primary completion date: Sep 2028 --> Dec 2030
    Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • albumin-bound paclitaxel • eribulin mesylate
    2ms
    Sustained disease control in ovarian carcinosarcoma treated with postoperative hyperthermic intraperitoneal chemotherapy and targeted maintenance: a case report. (PubMed, Front Med (Lausanne))
    After cytoreductive surgery, she received postoperative HIPEC followed by adjuvant chemotherapy nab-paclitaxel and carboplatin, then sequential maintenance therapy with bevacizumab followed by olaparib based on homologous recombination deficiency (HRD) positivity. The patient remained progression-free with good performance status at 24 months of follow-up. This hypothesis-generating case suggests that for selected patients with OCS, a multimodal approach incorporating aggressive cytoreductive surgery, postoperative HIPEC, and HRD-guided sequential maintenance therapy may warrant further investigation.
    Journal
    |
    HRD (Homologous Recombination Deficiency)
    |
    HRD
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • carboplatin • albumin-bound paclitaxel
    2ms
    GIANT: Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread (clinicaltrials.gov)
    P2, N=176, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Trial primary completion date: Jun 2026 --> Mar 2026
    Trial primary completion date
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    gemcitabine • albumin-bound paclitaxel • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • fluorouracil topical
    2ms
    BGB-A317-15025-101: BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=157, Completed, BeiGene | Active, not recruiting --> Completed
    Trial completion
    |
    cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • capecitabine • albumin-bound paclitaxel • pemetrexed • oxaliplatin • BGB-15025
    2ms
    AURORAS-1: A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=600, Recruiting, Erasca, Inc. | N=200 --> 600
    Enrollment change • First-in-human
    |
    Keytruda (pembrolizumab) • gemcitabine • Vectibix (panitumumab) • albumin-bound paclitaxel